success in collaborative endeavors is just as much a testament to the
company's innovative platforms as is the unique skill set and
personalities of its employees. As such, our team welcomes the
opportunity to collaborate with other firms dedicated to trailblaze a
path towards effective solutions for type 2 diabates. In addition to
several ongoing or pending SBIR/STTR collaborative projects,
NuPotential is engaged in preliminary discussion with several major
firms who stand to benefit from its breakthrough reprogramming platform
(cell line creation) as well as its novel epidrug libraries (type 2
diabetes and cancer therapies). NuPotential's core area of interest
of novel and/or first in class, epigenetic-based pharmaceuticals
targeting type 2 diabates and related indications.
of NuPotential’s proprietary cell reprogramming technology for disease
model cell line, cell therapeutic or diagnostic applications..
- Joint research for epigenetic-based biomarker elucidation in respect to type 2 diabetes and related indications.
- Joint research for regenerative medicine therapies in respect to type 2 diabetes and related indications.
- Other activities related to epigenetic-based, type 2 diabetes therapies and/or tools on a case-by-case basis.
Louisiana Emerging Technology Center, 340, E. Parker Blvd., Baton Rouge, LA 70803 • 225/615-8955
Copyright© 2012 NuPotential, Inc. All rights reserved.